Article

Pluripotent stem cell-derived natural killer cells for cancer therapy

Department of Medicine and Stem Cell Institute, University of Minnesota, Minneapolis, MN 55455, USA.
Translational research : the journal of laboratory and clinical medicine 09/2010; 156(3):147-54. DOI: 10.1016/j.trsl.2010.07.008
Source: PubMed

ABSTRACT Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) provide an accessible, genetically tractable, and homogenous starting cell population to efficiently study human blood cell development. These cell populations provide platforms to develop new cell-based therapies to treat both malignant and nonmalignant hematological diseases. Our group previously demonstrated the ability of hESC-derived hematopoietic precursors to produce functional natural killer (NK) cells as well as an explanation of the underlying mechanism responsible for the inefficient development of T and B cells from hESCs. hESCs and iPSCs, which can be engineered reliably in vitro, provide an important new model system to study human lymphocyte development and produce enhanced cell-based therapies with the potential to serve as a "universal" source of antitumor lymphocytes. This review will focus on the application of hESC-derived NK cells with currently used and novel therapeutics for clinical trials, barriers to translation, and future applications through genetic engineering approaches.

Download full-text

Full-text

Available from: Dan S Kaufman, Nov 17, 2014
0 Followers
 · 
92 Views
  • Source
    • "This approach could generate novel insights into NK cell turnover, differentiation, migratory behavior , in vivo killing of target cells, and other areas. Moreover, induced pluripotent stem cells have been used to generate hNK cells with antiviral activity against HIV (Knorr and Kaufman, 2010). NK cells derived from induced rhesus pluripotent stem cells (Liu et al., 2008) could be used to monitor in vivo NK cell development and differentiation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Human NK (hNK) cells play a key role in mediating host immune responses against various infectious diseases. For practical reasons, the majority of the data on hNK cells has been generated using peripheral blood lymphocytes. In contrast, our knowledge of NK cells in human tissues is limited, and not much is known about developmental pathways of hNK cell subpopulations in vivo. Although research in mice has elucidated a number of fundamental features of NK cell biology, mouse, and hNK cells significantly differ in their subpopulations, functions, and receptor repertoires. Thus, there is a need for a model that is more closely related to humans and yet allows experimental manipulations. Non-human primate models offer numerous opportunities for the study of NK cells, including the study of the role of NK cells after solid organ and stem cell transplantation, as well as in acute viral infection. Macaque NK cells can be depleted in vivo or adoptively transferred in an autologous system. All of these studies are either difficult or unethical to carry out in humans. Here we highlight recent advances in rhesus NK cell research and their parallels in humans. Using high-throughput transcriptional profiling, we demonstrate that the human CD56(bright) and CD56(dim) NK cell subsets have phenotypically and functionally analogous counterparts in rhesus macaques. Thus, the use of non-human primate models offers the potential to substantially advance hNK cell research.
    Frontiers in Immunology 02/2013; 4:32. DOI:10.3389/fimmu.2013.00032
  • Source
    09/2010; 156(3):107-11. DOI:10.1016/j.trsl.2010.07.007
  • [Show abstract] [Hide abstract]
    ABSTRACT: One of the key problems in cancer gene therapy is the inefficient delivery of therapeutic transgenes to tumour sites, after the systemic injection of the viral vector. Hence, new vector discovery is extremely important for the improvement of gene therapy results. Previously, mammalian cells were proposed as new vector systems; however with recent advances in stem cell research this modality makes them more suitable candidates. Tumours are composed of both malignant and benign cells. As "benign" cell types are able to form blood vessels, and stroma, it has been hypothesised that exogenously administrated cells of a different kind would preferentially engraft at the stromal tumour site and could deliver cancer gene therapy vectors to tumours.
    Clinical and Translational Oncology 01/2011; 13(1):10-7. DOI:10.1007/s12094-011-0611-3 · 1.60 Impact Factor
Show more